

Special Issue

Social Media in Immunology and Immunotherapy

Message from the Guest Editors

Social media platforms have become an essential part of our daily lives. Facebook has close to 2.4 billion users, YouTube and Instagram 1 billion, Twitter 330 million and LinkedIn 310 million active users. Moreover, TikTok has become the favorite social media platform in the younger generation. The social media revolution has quickly impacted healthcare, with significant educational, informative, and knowledge exchange implications. The content analysis of social media platforms in the field of medicine and scientific research currently represents a hot topic for the international literature. In fact, over the last few years, the number of publications focusing on the use and contents of social media for medical/scientific purposes has grown exponentially. This process has also been amplified by the new needs identified due to the pandemic wave. Currently, the Immunology field has made numerous strides, ensuring the development of different types of vaccine for SARS-Cov2 in just a few months. This is just one of the various goals achieved by this sector: just think of the new existing therapies in modulating the immune system to respond to neoplastic disease.

Guest Editors

Dr. Gianluigi Califano

Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy

Dr. Simone Morra

1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
2. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/146087

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).